首页> 美国卫生研究院文献>Human Vaccines Immunotherapeutics >Cost-effectiveness of hepatitis A vaccination in Indonesia
【2h】

Cost-effectiveness of hepatitis A vaccination in Indonesia

机译:印度尼西亚甲肝疫苗接种的成本效益

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective This study aims to assess the cost-effectiveness of hepatitis A immunization in Indonesia, including an explicit comparison between one-dose and two-dose vaccines.Methods An age-structured cohort model based on a decision tree was developed for the 2012 Indonesia birth cohort. Using the model, we made a comparison on the use of two-dose and one-dose vaccines. The model involved a 70-year time horizon with 1-month cycles for children less than 2 years old and annually thereafter. Monte Carlo simulations were used to examine the economic acceptability and affordability of the hepatitis A vaccination.Results Vaccination would save US$ 3 795 148 and US$ 2 892 920 from the societal perspective, for the two-dose and one-dose vaccine schedules, respectively, in the context of hepatitis A treatment. It also would save 8917 and 6614 discounted quality-adjusted-life-years (QALYs), respectively. With the vaccine price of US$ 3.21 per dose, the implementation of single dose vaccine would yield an incremental cost-effectiveness ratio (ICER) of US$ 4933 per QALY gained versus no vaccination, whereas the two-dose versus one-dose schedule would cost US$ 14 568 per QALY gained. Considering the 2012 gross-domestic-product (GDP) per capita in Indonesia of US$ 3557, the results indicate that hepatitis A vaccination would be a cost-effective intervention, both for the two-dose and one-dose vaccine schedules in isolation, but two-dose vaccination would no longer be cost-effective if one-dose vaccination is a feasible option. Vaccination would be 100% affordable at budgets of US$ 71 408 000 and US$ 37 690 000 for the implementation of the two-dose and one-dose vaccine schedules, respectively.Conclusions The implementation of hepatitis A vaccination in Indonesia would be a cost-effective health intervention under the market vaccine price. Given the budget limitations, the use of a one-dose-vaccine schedule would be more realistic to be applied than a two-dose schedule. The vaccine price, mortality rate and discount rate were the most influential parameters impacting the ICERs.
机译:目的本研究旨在评估印度尼西亚进行甲型肝炎疫苗接种的成本效益,包括一剂和两剂疫苗的显式比较。方法针对2012年印度尼西亚出生的婴儿,建立基于决策树的年龄结构队列模型队列。使用该模型,我们比较了两剂和一剂疫苗的使用情况。该模型涉及一个70岁以下的时间跨度,对于2岁以下的儿童为期1个月,之后每年一次。蒙特卡罗模拟用于检验甲型肝炎疫苗的经济可接受性和可承受性。结果从社会角度来看,对于两剂和一剂疫苗的接种,疫苗接种将节省3 795 148美元和2 892 920美元。分别在甲肝治疗的背景下。它还可以分别节省8917和6614折后的质量调整生命年(QALY)。疫苗价格为每剂3.21美元,与未接种疫苗相比,单剂疫苗的实施将使每获得QALY的成本效益比(ICER)达到4933美元,而两剂和一剂的时间表每个QALY成本为14568美元。考虑到印度尼西亚2012年的人均国内生产总值(GDP)为3557美元,结果表明,对于单独接种两剂和一剂疫苗,甲肝疫苗接种将是一种具有成本效益的干预措施,但是,如果一剂疫苗是可行的选择,那么两剂疫苗将不再具有成本效益。实施两剂和一剂疫苗方案的预算分别为71 408 000美元和37 690 000美元,可以100%负担得起的疫苗接种。结论在印度尼西亚实施甲型肝炎疫苗接种将是一项费用。市场疫苗价格下的有效健康干预。鉴于预算的限制,一剂疫苗时间表的使用要比两剂时间表更为现实。疫苗价格,死亡率和折现率是影响ICER的最具影响力的参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号